false
0001727196
0001727196
2024-02-15
2024-02-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event Reported): February 15, 2024
Scholar Rock Holding Corporation
(Exact Name of Registrant as Specified in Charter)
Delaware |
001-38501 |
82-3750435 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
|
|
|
301 Binney Street, 3rd Floor, Cambridge, MA 02142 |
(Address of Principal Executive Offices) (Zip Code) |
(857) 259-3860
(Registrant's telephone
number, including area code)
(Former name or
former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
Trading
Symbol(s) |
Name of each exchange
on which registered |
Common Stock, par value $0.001 per share |
SRRK |
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR §240.12b-2). Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 15, 2024, the Board of Directors (the “Board”)
of Scholar Rock Holding Corporation (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee,
increased the size of the Board to eleven (11) directors and subsequently appointed Katie Peng to join the Board, effective February 15,
2024, filling the vacancy created by the increase in the size of the Board. The Board determined that Ms. Peng is independent under
the listing standards of NASDAQ and the Company’s corporate governance guidelines. Ms. Peng will serve as a Class II director
with a term expiring at the annual meeting of stockholders to be held in 2026.
As a non-employee director, Ms. Peng will receive cash compensation
and an equity award for her Board service, in accordance with the Company’s non-employee director compensation policy, as amended
from time to time. Ms. Peng is not a party to any transaction with the Company that would require disclosure under Item 404(a) of
Regulation S-K, and there are no arrangements or understandings between Ms. Peng and any other persons pursuant to which she was
selected as a director. In addition, Ms. Peng will enter into an indemnification agreement with the Company consistent with the form
of the existing indemnification agreement entered into between the Company and its non-employee directors.
On February 15, 2024, Amir Nashat informed the Company that he
will not stand for reelection as a Class II director at the Company’s annual meeting of stockholders in 2024 (the “Annual
Meeting”). Mr. Nashat’s decision to not stand for reelection was not the result of any disagreement with the Company
or any matter relating to the Company’s operations, policies or practices. Mr. Nashat will continue to serve as a member of
the Board and a member of the Audit Committee of the Board (the “Audit Committee”) until the Annual Meeting. In connection
with Ms. Peng’s appointment as a member of the Board, the Board also appointed her to the Audit Committee, effective as of
the Annual Meeting, upon Mr. Nashat’s departure from the Board and the Audit Committee. Following the appointment of Ms. Peng,
the Company’s Audit Committee will consist of Joshua Reed (Chair), Richard Brudnick and Ms. Peng. The compositions of the Compensation
Committee, the Nominating and Corporate Governance Committee, and the Science, Innovation & Technology Committee will remain
unchanged.
On February 15, 2024, the Company issued a press release announcing
the appointment of Ms. Peng to the Board. A copy of this press release is furnished as Exhibit 99.1 to this report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release issued by the Company on February 15, 2024, furnished hereto.
104 Cover Page Interactive Data.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Scholar Rock Holding Corporation |
|
|
|
Date: February 15, 2024 |
By: |
/s/ Junlin Ho |
|
|
Junlin Ho |
|
|
General Counsel & Corporate Secretary |
Exhibit 99.1
Scholar Rock Announces
the Addition of Katie Peng to Its Board of Directors and
Promotes Mo Qatanani,
Ph.D. to Chief Scientific Officer
CAMBRIDGE, Mass.--(BUSINESS
WIRE)— February 15, 2024-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical
company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases
where protein growth factors play a fundamental role, today announced the appointment of Katie Peng to Scholar Rock’s Board
of Directors and the promotion of Mo Qatanani, Ph.D., to Chief Scientific Officer.
“We are pleased to welcome Katie to
Scholar Rock’s Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,”
said David Hallal, Chairman of the Board of Scholar Rock. “Katie brings deep commercial expertise in neurology and rare diseases
and has a strong understanding of SMA from her experience launching Evrysdi while she was a business unit head at Genentech. Katie joining
our Board reflects the continued evolution of Scholar Rock, and as part of this process, Amir Nashat will be stepping down from the Board
at this year’s annual shareholder meeting. Amir has made significant contributions to the growth of Scholar Rock since joining the
board in 2012, and we extend our sincere gratitude to him for his unwavering dedication to the company.”
Ms. Peng is an accomplished biotechnology
executive with over three decades of deep commercial experience in neurology and rare diseases, and she is currently the Chief Commercial
Officer at Denali Therapeutics. Prior to joining Denali, Ms. Peng managed a neurology, ophthalmology, immunology, and rare disease
portfolio representing approximately $14 billion in revenue at Genentech. She has successfully launched multiple products in neurology,
oncology, and rare disease, notably Evrysdi® (risdiplam) at Genentech, a medicine used to treat spinal muscular atrophy (SMA) in adults
and children. Before that, Ms. Peng was at Roche Holding AG, where she was the General Manager of both Taiwan and Singapore, managing
the portfolio of over 30 products in the Asia Pacific region. Earlier in her career, she held multiple commercial roles at Amgen Inc.
and was a research scientist at Allergan plc. Ms. Peng holds an MBA from the Kelley School of Business, Indiana University and
a B.A. from the University of California, Berkeley. She also serves as a board member for California Life Sciences and Adicet Bio.
“I am thrilled to join Scholar Rock’s
Board of Directors as the company prepares for its first potential commercial launch of apitegromab. I look forward to working with the
team and sharing my experience and expertise to successfully bring apitegromab to people living with SMA,” said Ms. Peng.
“In addition to having Katie join our
Board, I am excited by the continued progress of our preclinical programs, including additional work in developing SRK-439 for cardiometabolic
disorders. Mo has been a driving force in advancing our early-stage pipeline, especially the cardiometabolic program, and it is my pleasure
to announce his promotion to Chief Scientific Officer. He has been an outstanding leader of our research organization and a key member
of the leadership team,” said Jay Backstrom, M.D., MPH, President and Chief Executive Officer of Scholar Rock.
Dr. Qatanani joined Scholar Rock in 2021
and, since 2022, has been leading all research functions, including discovery biology, protein sciences & antibody engineering,
nonclinical safety, and translational sciences. He brings over 15 years of discovery and translational research experience in developing
and advancing multiple therapeutic modalities in the neuromuscular and cardiometabolic disease areas.
Prior to Scholar Rock, Dr. Qatanani was
a founding employee, vice president, and Head of Research at Dyne Therapeutics, where he built the research organization from the ground
up to launch and advance to the clinic multiple therapeutic programs for rare neuromuscular diseases. Before that, he held research positions
of increasing responsibility at Alexion Pharmaceuticals, Synageva BioPharma, and Merck. Dr. Qatanani holds a Ph.D. in Molecular and
Human Genetics from Baylor College of Medicine and completed a post-doctoral fellowship at the Institute for Diabetes, Obesity and Metabolism
at the University of Pennsylvania School of Medicine. He has a B.Sc. and a M.Sc. in Biology from the American University of Beirut.
“Scholar Rock is known for its pioneering
scientific research, particularly in the unparalleled selective targeting of the latent forms of growth factors, and I am proud to be
able to lead these efforts during this exciting stage of the company’s growth, and to help translate this groundbreaking science
into transformative therapies that have the potential to improve peoples’ lives,” said Dr. Qatanani.
About Scholar Rock
Scholar Rock is a biopharmaceutical company that discovers, develops,
and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of
the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to
protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental.
Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease,
cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.
Scholar Rock is the only company to show clinical proof of concept
for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches
is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth
factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through
traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com
and follow @ScholarRock and on LinkedIn.
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our investors
and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations
and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well
as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information.
As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis.
The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended.
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
Forward-Looking Statements
This press release contains "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar
Rock’s future expectations, plans and prospects, including without limitation, Scholar Rock’s expectations regarding its growth,
strategy, progress and development timing, the ability of any individual to affect the growth, strategy, and progress of Scholar
Rock, and the potential of its product candidates and proprietary platform. The use of words such as “may,” “might,”
“could,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,”
“estimate,” “project,” “intend,” “future,” “potential,” or “continue,”
and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based
on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties
include, without limitation, Scholar Rock’s ability to provide the financial support, resources and expertise necessary to identify
and develop product candidates on the expected timeline, the data generated from Scholar Rock’s nonclinical and preclinical studies
and clinical trials, and Scholar Rock’s ability to manage expenses and to obtain additional funding when needed to support its business
activities and establish and maintain strategic business alliances and new business initiatives, as well as those risks more fully discussed
in the section entitled "Risk Factors" in Scholar Rock’s Quarterly Report on Form 10-Q for the year ended September 30,
2023, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock’s subsequent filings
with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock’s views only as of today
and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the
date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.
Scholar Rock:
Investors & Media
Rushmie Nofsinger
Scholar Rock
rnofsinger@scholarrock.com
ir@scholarrock.com
857-259-5573
Molly MacLeod
Scholar Rock
mmacleod@scholarrock.com
media@scholarrock.com
802-579-5995
v3.24.0.1
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Grafico Azioni Scholar Rock (NASDAQ:SRRK)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Scholar Rock (NASDAQ:SRRK)
Storico
Da Set 2023 a Set 2024